The case for & against
Bull & Bear analysis
InMode Ltd. (NASDAQ: INMD) is a leading player in the medical aesthetics sector, specializing in minimally invasive aesthetic medical technology, primarily providing innovative solutions for plastic surgery and dermatology. InMode operates in over 100 countries and has built a strong portfolio focused on laser-based technologies targeted at both static and dynamic aesthetic treatments. The company is currently navigating changing market dynamics, particularly influenced by macroeconomic headwinds, while striving to strengthen operational efficiencies and expand its reach into emerging markets.
Bull says
- ↑Market leader in minimally invasive aesthetic devices; launched new CO2 lasers
- ↑Q1 2026 revenue $82 M (+5% YoY); international sales 48% of total
- ↑Repurchased $127 M in 2025 and $52 M YTD 2026 in shares
- ↑Attractive valuation: high earnings yield and low book-to-price ratio
- ↑Cash position $537 M supports operations, buybacks, and M&A optionality
- ↑Retail sentiment surged after unsolicited buyout at 21% premium
Bear says
- ↓Q1 2026 revenue fell 6% YoY to $82 M; GAAP EPS $0.18 vs. $0.26
- ↓Gross margin declined to 75% due to higher cost of goods
- ↓Operating expenses +13.7% YoY to $51.5 M, straining profitability
- ↓Weak growth and revision factors suggest potential value trap
- ↓Rising non-invasive alternatives intensify competitive pressures
- ↓High price volatility risk may amplify downside swings
Investment themes with INMD
Clinical instruments and devices powering patient care
Miscellaneous or uncategorized companies
Earnings Call · Q1 2026 · Mgmt. Guidance
Transcript signals
Bull points
- In addition, we're seeing early signs of stabilization, particularly in the US, and believe that this quarter reinforced our confidence that 2026 is moving in the right direction.
- reinforcing our confidence that these changes are beginning to bear fruit.
- Argentina. Argentina was established late 2025. It took us some time, two months, to get all the clearances from the regulatory body in Argentina under our name in our subsidiary. Now everything is almost ready. We have an office. We have one or two salespeople. We have a clinical trainer, we have a manager, and hopefully, Q2 in 2026, we will see some results. Until now, it was more like a setup, organizing all the regulatory clearances. Hopefully, Q2 in this year, they will start delivering cells as well. Argentina is not very big country compared to Brazil and others, but we believe that there is a market there.
Bear points
- Demand for static procedures was again pressured in the first quarter of 2026 by microeconomic headwind.
- so far, no.
- so far, no.